

1. [BRIEF-Merck and Moderna announce strategic collaboration](#) – Reuters

Merck and Moderna announce strategic collaboration to advance novel mRNA-based personalized cancer vaccines with Keytruda (pembrolizumab) for the treatment of multiple types of cancer.

2. [U.S. FDA names Pazdur head of new Oncology Center of Excellence](#) – Reuters

The U.S. Food and Drug Administration's high-profile cancer drug director, Dr. Richard Pazdur, has been named head of a newly created Oncology Center of Excellence that will coordinate the review of all the agency's cancer therapeutics. The announcement was made on Wednesday by Vice President Joseph Biden during a summit to discuss the latest developments in the White House's \$1 billion "Moonshot" project to accelerate cancer research.

3. [Limited protection of GSK's malaria vaccine dwindles in 7 years](#) – Reuters

The world's first malaria vaccine, developed by GlaxoSmithKline, provides some protection after three doses but its effect dwindles to almost nothing after seven years, scientists said on Wednesday. Publishing a long-term study of the vaccine - called RTS,S or Mosquirix and designed for children in Africa where the disease claims most of its victims - researchers said the decline in its efficacy over time is fastest in children living in areas with higher than average rates of malaria.

4. ["We are seeing increasing use of our systems by Indian enterprises"](#) – Business Today

In an interview, Joe C. Mathew, WIPO Director General Francis Gurry talks about the emerging areas in intellectual property. "We may not be able to project any number related to copyright registrations, because IP is for long-term gains. But we see increased interest in patent and trade mark filings, especially in the branding area. There are over 200,000 trademark registrations in India. The conversion rate into international trademarks is an indication of the growing interest of Indian firms to reach out to global markets or increase their external relations. Through this system Indian enterprises can move to major import markets such as the EU, the US, China, South-East Asia, Australia and Japan. The Incredible India campaign was essentially a branding exercise that helped India," he said.

1. [BRIEF-Merck and Moderna announce strategic collaboration](#) – Reuters
2. [U.S. FDA names Pazdur head of new Oncology Center of Excellence](#) – Reuters
3. [Limited protection of GSK's malaria vaccine dwindles in 7 years](#) – Reuters
4. ["We are seeing increasing use of our systems by Indian enterprises"](#) – Business Today
5. [Doors Wide Open?](#) – Business Today
6. [Research Discovery](#) – Business Today
7. [Shortage of cancer and other drugs in Kerala hospitals](#) – The Times of India
8. [UIPS in for overhaul](#) – The Times of India
9. [Pharmacies warned against selling drugs at excess rates](#) – The Hindu
10. [Roche Diagnostics' Nucleic Acid Amplification Technology detects TTIs](#) – The New Indian Express
11. [Targeting of China is not a great idea](#) – The Asian Age
12. [Suven Life Sciences gets patent for neuro-degenerative drug](#) – ET Healthworld.com
13. [Karnataka pharma industry in wait & watch mode on Brexit impact](#) – Pharmabiz.com
14. [Health ministry issues Revised Draft Guidelines on Similar Biologics](#) – Pharmabiz.com

5. [Doors Wide Open? – Business Today](#)

India claims to be the most FDI-friendly economy in the world, but the fact that India has been one of the most attractive FDI destinations globally ever since the Modi government took charge two years ago cannot be ignored. The \$55.46-billion inflow in 2015/16 was the highest ever, and the \$45.15 billion in 2014/15 was the second highest. True, approximately one-fifth of these inflows during both the years were re-invested earnings of foreign companies operating in India (as India's FDI figure is a combination of all types of foreign investments including remittances from non-resident-Indians), but the trend pretty much remains the same.

6. [Research Discovery – Business Today](#)

Two years after Japanese pharmaceutical major Daiichi Sankyo acquired controlling stake in Ranbaxy Laboratories, India's biggest pharma company of the time, another small, yet significant transaction happened between the two parties (Ranbaxy was still listed as a separate company then). On July 2, 2010, Daiichi Sankyo and Ranbaxy announced that the latter's New Drug Discovery Research had been transferred to Daiichi Sankyo India Pharma Private Limited, and rechristened Daiichi Sankyo Life Science Research Center in India (abbreviated to RCI).

7. [Shortage of cancer and other drugs in Kerala hospitals – The Times of India](#)

The government's move to curb prices of essential medicines has had an unexpected fallout — several drugs, including those for liver treatment, cancer, dog and snake bites and even IV saline, are either in short supply or have gone missing from hospitals and chemist shops.

Sources said that while IV saline is in short supply even in government hospitals, few major private hospitals have rescheduled cancer treatments due to shortage of drugs.

8. [UIPS in for overhaul – The Times of India](#)

With a high-tech mammalian cell culture lab, sophisticated instrument lab and four research labs for students, the University Institute of Pharmaceutical Sciences (UIPS), PU, is in for a major facelift in the 2016-17 academic session. UIPS has been allocated the top floor of the department to set up high-tech labs. Besides, there will be one common room for boys and one for girls, store rooms, three lecture halls, faculty rooms and an exam room.

9. [Pharmacies warned against selling drugs at excess rates – The Hindu](#)

Wholesale and retail druggists in Kozhikode district have been warned against selling medicines at excess rates. The warning comes close on the heels of the National Pharmaceutical Pricing Authority (NPPA), on June 4, notifying the revised rates of 33 medicines for different treatments including cancer, diabetes and hypertension. Assistant Drugs Controller P.M. Jayan said that a meeting of registered pharmacists and proprietors of medical stores had been held at the District Collectorate in this regard. They had already been apprised of implementing the revised prices. Stringent action would also be taken against those merchandising the drugs without prescription from medical practitioners, he said.

10. [Roche Diagnostics' Nucleic Acid Amplification Technology detects TTIs – The New Indian Express](#)

While transfusion transmitted infections (TTIs) have surged in Odisha recently, the range increased from 0.04 per cent to 1.35 per cent between 2010 and 2015. In the first week of this month, when Roche Diagnostics launched Nucleic Acid Amplification Technology (NAT) in the State, at least four cases of HIV and HBV infected blood were reported in two top State Government hospitals, Dr Sandeep Sewlikar, Head - Medical Affairs, Roche Diagnostics India, said during a telecon with this paper today. These four cases were detected using the NAT in association with the State Government. NAT PCR solution enables screening of donated blood to reduce the risk of people receiving blood. With the high prevalence rate of TTIs in India, NAT's role in enabling access to safe blood is significant.

11. [Targeting of China is not a great idea](#) – **The Asian Age**

In an opinion piece, Patralekha Chatterjee, who focuses on development issues of India, states how China is vital for Indian pharma industry. “If China decides to stop its supply of intermediates and other raw materials, it will affect India’s pharma industry and bring it almost to a halt,” she said in her piece. She also said, “India and China are linked in many different ways in strategic spheres. Take just one: medicines. India is among the world’s leading low-cost generic drugmakers. But most of the Active Pharmaceutical Ingredients (API) or bulk drugs necessary to produce these medicines come from just one country: China. APIs are what give a medicine its therapeutic effect. India’s dependence on China for APIs has been an area of concern for years. Dr Yusuf Hamied, Indian scientist and businessman, and chairman of Cipla, the country’s oldest pharmaceutical company, once famously said, “If China decided one bright day to stop exports to India, we would be finished. The pharma industry is zero, both domestic and export, and we’re looking at that danger objectively.”

12. [Suven Life Sciences gets patent for neuro-degenerative drug](#) – **ET Healthworld.com**

Drug firm Suven Life Sciences has been granted a patent from Europe and two product patents from Eurasia for a drug used in the treatment of neuro-degenerative diseases. In a BSE filing today, Suven Life said it has been granted "one product patent from Europe and two product patents from Eurasia corresponding to New Chemical Entities (NCEs) for treatment of disorders associated with neuro-degenerative diseases".

13. [Karnataka pharma industry in wait & watch mode on Brexit impact](#) – **Pharmabiz.com**

Some members of the Karnataka pharma industry feel that Brexit can affect their ease of access with European Union in future. Fall of the Euro and pound can erode the profit margins adversely affecting the revenue growth of the companies. Large companies like Biocon and Strides trade mostly in US dollars with limited exposure to GBP. But small and medium sized companies which are looking for an entry into EU informed that the Brexit comes as a trade barrier in the European Union.

14. [Health ministry issues Revised Draft Guidelines on Similar Biologics](#) – **Pharmabiz.com**

The Union health ministry has issued the 'Revised Draft Guidelines on Similar Biologics' to lay down the regulatory pathway for marketing authorization of similar biologics in the country. These guidelines, prepared by Central Drugs Standard Control Organization (CDSCO) and the Department of Biotechnology (DBT), address the regulatory pathway regarding manufacturing process and safety, efficacy and quality aspects for similar biologics. These guidelines also address the pre-market regulatory requirements including comparability exercise for quality, preclinical and clinical studies and post-market regulatory requirements for similar biologics. These guidelines are for the guidance of all stakeholders and are not meant to substitute or rephrase the Rules made under Drugs and Cosmetics Act, 1940 or any other relevant Acts and are subject to being in conformity with the Drugs and Cosmetics Act and Rules as may be amended from time to time